×
S&P 500   3,901.59 (+0.04%)
DOW   31,539.96 (+0.32%)
QQQ   290.30 (-0.74%)
AAPL   140.62 (-0.73%)
MSFT   261.77 (-1.18%)
META   168.55 (-0.55%)
GOOGL   2,282.97 (-1.45%)
AMZN   110.44 (-2.46%)
TSLA   724.96 (-1.33%)
NVDA   164.32 (-2.59%)
NIO   22.23 (-3.14%)
BABA   119.02 (+0.24%)
AMD   82.85 (-3.84%)
MU   59.42 (+1.09%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.08 (+0.55%)
F   12.21 (+1.41%)
DIS   99.98 (+3.49%)
AMC   13.74 (-2.76%)
PFE   51.33 (-1.06%)
PYPL   74.92 (-1.34%)
NFLX   185.82 (-1.76%)
S&P 500   3,901.59 (+0.04%)
DOW   31,539.96 (+0.32%)
QQQ   290.30 (-0.74%)
AAPL   140.62 (-0.73%)
MSFT   261.77 (-1.18%)
META   168.55 (-0.55%)
GOOGL   2,282.97 (-1.45%)
AMZN   110.44 (-2.46%)
TSLA   724.96 (-1.33%)
NVDA   164.32 (-2.59%)
NIO   22.23 (-3.14%)
BABA   119.02 (+0.24%)
AMD   82.85 (-3.84%)
MU   59.42 (+1.09%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.08 (+0.55%)
F   12.21 (+1.41%)
DIS   99.98 (+3.49%)
AMC   13.74 (-2.76%)
PFE   51.33 (-1.06%)
PYPL   74.92 (-1.34%)
NFLX   185.82 (-1.76%)
S&P 500   3,901.59 (+0.04%)
DOW   31,539.96 (+0.32%)
QQQ   290.30 (-0.74%)
AAPL   140.62 (-0.73%)
MSFT   261.77 (-1.18%)
META   168.55 (-0.55%)
GOOGL   2,282.97 (-1.45%)
AMZN   110.44 (-2.46%)
TSLA   724.96 (-1.33%)
NVDA   164.32 (-2.59%)
NIO   22.23 (-3.14%)
BABA   119.02 (+0.24%)
AMD   82.85 (-3.84%)
MU   59.42 (+1.09%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.08 (+0.55%)
F   12.21 (+1.41%)
DIS   99.98 (+3.49%)
AMC   13.74 (-2.76%)
PFE   51.33 (-1.06%)
PYPL   74.92 (-1.34%)
NFLX   185.82 (-1.76%)
S&P 500   3,901.59 (+0.04%)
DOW   31,539.96 (+0.32%)
QQQ   290.30 (-0.74%)
AAPL   140.62 (-0.73%)
MSFT   261.77 (-1.18%)
META   168.55 (-0.55%)
GOOGL   2,282.97 (-1.45%)
AMZN   110.44 (-2.46%)
TSLA   724.96 (-1.33%)
NVDA   164.32 (-2.59%)
NIO   22.23 (-3.14%)
BABA   119.02 (+0.24%)
AMD   82.85 (-3.84%)
MU   59.42 (+1.09%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.08 (+0.55%)
F   12.21 (+1.41%)
DIS   99.98 (+3.49%)
AMC   13.74 (-2.76%)
PFE   51.33 (-1.06%)
PYPL   74.92 (-1.34%)
NFLX   185.82 (-1.76%)
NYSE:TEVA

Teva Pharmaceutical Industries Stock Forecast, Price & News

$8.16
-0.05 (-0.61%)
(As of 06/28/2022 10:47 AM ET)
Add
Compare
Today's Range
$8.13
$8.33
50-Day Range
$7.38
$10.18
52-Week Range
$7.23
$10.50
Volume
186,545 shs
Average Volume
9.86 million shs
Market Capitalization
$9.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.71
30 days | 90 days | 365 days | Advanced Chart

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock Forecast (MarketRank)

Overall MarketRank

2.23 out of 5 stars

Medical Sector

346th out of 1,436 stocks

Pharmaceutical Preparations Industry

150th out of 687 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
Teva Pharmaceutical Industries logo

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

TEVA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
37,537
Year Founded
N/A

Company Calendar

Last Earnings
5/03/2022
Today
6/28/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.71
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+31.3%
Consensus Rating
Hold
Rating Score (0-4)
2.125
Research Coverage
8 Analysts

Profitability

Net Income
$417 million
Pretax Margin
-2.94%

Debt

Sales & Book Value

Annual Sales
$15.88 billion
Cash Flow
$3.89 per share
Book Value
$10.19 per share

Miscellaneous

Outstanding Shares
1,103,330,000
Free Float
1,094,283,000
Market Cap
$9.00 billion
Optionable
Optionable
Beta
1.17














Teva Pharmaceutical Industries Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2022?

8 brokerages have issued 12 month price targets for Teva Pharmaceutical Industries' stock. Their TEVA stock forecasts range from $7.00 to $14.00. On average, they predict Teva Pharmaceutical Industries' share price to reach $10.71 in the next year. This suggests a possible upside of 31.0% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
or view top-rated stocks among Wall Street analysts.

How has Teva Pharmaceutical Industries' stock price performed in 2022?

Teva Pharmaceutical Industries' stock was trading at $8.01 on January 1st, 2022. Since then, TEVA shares have increased by 2.1% and is now trading at $8.18.
View the best growth stocks for 2022 here
.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Teva Pharmaceutical Industries
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Tuesday, May, 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.53. The business had revenue of $3.66 billion for the quarter, compared to analyst estimates of $3.75 billion. Teva Pharmaceutical Industries had a negative net margin of 3.95% and a positive trailing twelve-month return on equity of 24.04%. The business's revenue was down 8.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 earnings per share.
View Teva Pharmaceutical Industries' earnings history
.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $2.40-$2.60 for the period, compared to the consensus estimate of $2.51. The company issued revenue guidance of $15.40 billion-$16.00 billion, compared to the consensus revenue estimate of $15.97 billion.

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kare Schultz, Pres, CEO & Director (Age 61, Pay $4.68M)
  • Mr. Eliyahu Sharon Kalif, Exec. VP & CFO (Age 49, Pay $1.74M)
  • Mr. Eric Drape, Exec. VP of Global Operations (Age 60, Pay $1.91M) (LinkedIn Profile)
  • Mr. Mark Sabag, Exec. VP of International Markets Commercial (Age 51, Pay $1.79M) (LinkedIn Profile)
  • Dr. Sven Dethlefs Ph.D., Exec. VP of North America Commercial (Age 53, Pay $1.72M)
  • Mr. Amir Weiss, Sr. VP & Chief Accounting Officer (Age 45)
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations
  • Mr. David M. Stark, Exec. VP & Chief Legal Officer (Age 53)
  • Ms. Lori Queisser, Sr. VP & Global Compliance Officer
  • Ms. Galia Inbar, Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG (Age 47)

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries CEO Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among Teva Pharmaceutical Industries' employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.98%), BlackRock Inc. (3.77%), Menora Mivtachim Holdings LTD. (2.11%), Migdal Insurance & Financial Holdings Ltd. (1.89%), Phoenix Holdings Ltd. (1.51%) and State Street Corp (1.41%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries
.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Group One Trading L.P., UBS Group AG, BNP Paribas Arbitrage SA, Citigroup Inc., Wolverine Asset Management LLC, JPMorgan Chase & Co., and SG Americas Securities LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last two years include David Matthew Stark, Eli Shani, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane, and Sven Dethlefs.
View insider buying and selling activity for Teva Pharmaceutical Industries
or view top insider-selling stocks.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was bought by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Bank of Montreal Can, Allianz Asset Management GmbH, Renaissance Technologies LLC, Phoenix Holdings Ltd., BlackRock Inc., Dimensional Fund Advisors LP, and Meitav Dash Investments Ltd..
View insider buying and selling activity for Teva Pharmaceutical Industries
or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $8.18.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $9.03 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($0.550010) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries employs 37,537 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for Teva Pharmaceutical Industries is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at [email protected], or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.